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Non-Melanoma Skin Cancer Incidence and Impact of
Skin Cancer Screening on Incidence
Nora Eisemann1, Annika Waldmann2, Alan C. Geller3, Martin A. Weinstock4,5,6, Beate Volkmer7,
Ruediger Greinert7, Eckhard W. Breitbart7,8 and Alexander Katalinic1,2
Non-melanoma skin cancer (NMSC) is the most common malignancy, whose public health significance is often
unrecognized. This analysis has two objectives: first, to provide up-to-date incidence estimates by sex, age group,
histological type, and body site; and second, to study the impact of skin cancer screening. The impact of
screening on NMSC incidence in Schleswig-Holstein, Germany, is analyzed by comparing four time periods of
different screening settings (no screening (1998–2000), pilot project (Skin Cancer Research to Provide Evidence for
Effectiveness of Screening in Northern Germany, SCREEN, 2003–2004), after SCREEN (2004–2008), and nation-wide
skin cancer screening (2008–2010)) to a reference region (Saarland, Germany). Age-standardized (Europe) NMSC
incidence was 119/100,000 for women and 145/100,000 for men in the most recent screening period in Schleswig-
Holstein (2008–2010). During implementation of SCREEN (2003–2004), incidence increased from 81.5/100,000 to
111.5/100,000 (1998–2000) by 47% for women and 34% for men. All age groups in women were affected by the
increase, but increases for men were mostly limited to the older age groups. Incidence in Saarland first increased
slowly, but increased steeply with the introduction of the nation-wide skin cancer screening in 2008 (þ 47% for
women and þ 40% for men, reference 2004–2008). Observed changes are most likely attributed to screening
activities.
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INTRODUCTION
Non-melanoma skin cancer (NMSC) is the most frequent
malignancy in Germany and other mainly fair-skinned popu-
lations (Lomas et al., 2012). About 80% of all NMSC are basal
cell carcinoma (BCC), while squamous cell carcinomas (SCC)
represent about 20%, and other diagnoses represent only
1% (Katalinic et al., 2003). Unfortunately, NMSC is often not
routinely reported to cancer registries, hence accurate
estimates of incidence are difficult to obtain (Lomas et al.,
2012). Therefore, the world-wide burden of NMSC remains
unclear. The World Health Organization (WHO) estimates
2–3 million cases per year (World Health Organization,
2011), which are most likely to be under-reported, parti-
cularly in light of a recent study that estimated 3.5 million
cases each year in the United States (Rogers et al., 2010;
American Cancer Society, 2011). In Germany, in 2009, new
cases of NMSC were conservatively estimated at 120,000 per
year (Association of Population-based Cancer Registries in
Germany (GEKID), 2013); a recent estimate of 200,000 new
cases per year (including 30,000 in situ SCC) is likely to be
more accurate (Kraywinkel et al., 2012).
Although mortality from NMSC is rare in the general
population, treatment of NMSC poses a considerable burden
on the health-care system. In Germany, NMSC is often
treated in hospitals (including one overnight stay), resulting
in higher costs than in other countries that favor ambulant
treatment. According to the national information system of
the federal health monitoring in Germany, the yearly direct
costs for melanoma and NMSC together (unfortunately no
distinction is possible) in Germany amount to h503 million
(approximately $725 million; Statistisches Bundesamt, 2011).
Age-standardized hospitalization rates for NMSC in Germany
are 1.8-fold and 2.5-fold higher than rates for melanoma
among women and men, respectively, and annual hospita-
lization costs for NMSC were estimated to be approximately
twice the costs for melanoma (Stang et al., 2008). However, as
no outpatient data on skin cancer costs, neither for NMSC nor
for melanoma, are available for Germany, the total cost
estimates for NMSC remain incomplete.
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A detailed population-based description on NMSC in
Schleswig-Holstein, the northernmost federal state in
Germany, was published in 2003 (Katalinic et al., 2003)
showing the high burden of this type of skin cancer. In
2003–2004, a 1-year pilot project for population-based skin
cancer screening without personal invitation system (SCREEN,
Skin Cancer Research to Provide Evidence for Effectiveness of
Screening in Northern Germany) with the goal to reduce skin
cancer burden was conducted in Schleswig-Holstein (Breitbart
et al., 2012). With a participation rate of 27.0% in women and
10.4% in men, about 360,000 persons attended the skin
cancer screening and 42,500 NMSCs were diagnosed, i.e.,
42.4% of all incident NMSCs diagnosed in Schleswig-Holstein
during the SCREEN period were screening detected (Breitbart
et al., 2012). During the SCREEN period, 1,961 incident BCCs
were diagnosed (44.2% of all incident BCC), and 392 invasive
or in situ SCCs (27.7% of all incident invasive or in situ SCCs).
Design of this screening program and first results on
melanoma incidence and mortality are published elsewhere
(Breitbart et al., 2012; Katalinic et al., 2012; Waldmann et al.,
2012). Based on results of the pilot project, a similar skin
cancer screening was implemented nation wide in July 2008.
Two main aims are targeted in this report: first, an updated
description of NMSC incidence for a region with a compre-
hensive registration of skin cancer (Federal State of Schleswig-
Holstein, Germany) is provided. Second, the impact of the
pilot project and the implementation of the population-based
skin cancer screening on NMSC incidence in Schleswig-
Holstein is described by observing the incidence trends over
time and comparing them with the trends in a reference region
(Federal State of Saarland, Germany).
RESULTS
Frequencies and incidence rates of NMSC incidence in
Schleswig-Holstein for the pre-screening period (January
1998–December 2000) and the most recent screening period
(July 2008–December 2010) by sex, age group, histology, and
localization are provided in Table 1. In the latter time period,
7,302 women and 7,688 men were reported to the Schleswig-
Holstein Cancer Registry with a diagnosis of NMSC. This
corresponds to age-standardized incidence rates of 119.0 and
145.3 cases/100,000 for women and men with the European
standard population (and 82.8 and 96.0 cases/100,000 for
women and men with the world standard population). The
median age at diagnosis was 71 years in both women and
men with an interquartile range of 62–79 years for women and
65–77 years for men. The most common histological type of
NMSC was BCC (approximately 82% in women and 77% in
men), followed by SCC (approximately 17% in women and
22% in men). Adenocarcinoma (e.g., originating from gland
cells of the skin), sarcoma, Merkel cell carcinoma, and other
cancers each comprised 0.2 to 0.4% of all NMSCs.
NMSC occurred most frequently on the face (women: 45%
and men: 39%) and on the trunk (women: 18% and men:
19%). The body site distribution differed between women and
men (Po0.001): women were relatively more often affected in
the face, on the eyelid, and on leg and hip, while NMSC in
men occurred more often on the scalp and the external ear.
Second, for both Schleswig-Holstein and Saarland, the
impact of screening on NMSC incidence was analyzed by
comparing age-standardized incidence rates of the period
before the SCREEN project, (January 1998–December 2000),
the SCREEN period (July 2003–June 2004), the period between
SCREEN and German nation-wide skin cancer screening (July
2004–June 2008), and the period with nation-wide skin cancer
screening (July 2008–December 2010; Tables 2 and 3). In all
four periods, Saarland had a lower incidence than Schleswig-
Holstein. With the beginning of SCREEN in 2003–2004,
incidence increased significantly by 38/100,000 in Schleswig-
Holstein (þ 47% for women and þ34% for men) com-
pared with the pre-SCREEN period in 1998–2000, but
only 4/100,000 for women (þ7%) and 1/100,000 for men
(þ1%) in Saarland (not significant). During the period
after SCREEN, incidence in Schleswig-Holstein decreased
significantly by 6/100,000 ( 5% for women and 3% for
men) compared with the previous SCREEN period, while a
further (significant) increase by 7/100,000 for women (þ 13%)
and 9/100,000 for men (15%) was observed in Saarland. With
the uptake of the nation-wide skin cancer screening in July
2008, incidence in Schleswig-Holstein increased again by
6/100,000 for women (þ 5%) and 1/100,000 for men (þ1%)
(significant only for women) compared with the previous
period in July 2004–June 2008. In Saarland, where no
previous screening had been conducted, the increase from
July 2004–June 2008 to the period with nation-wide skin
cancer screening was significant and much more pronounced
(27/100,000 for women (þ 47%) and 36/100,000 for men
(þ40%)).
The incidence patterns are similar for the subgroups
of BCC and of SCC (Tables 2 and 3). The time trends for
BCC and SCC incidence in Schleswig-Holstein and Saarland,
including the different screening phases, are shown in
Figure 1a and b. In Schleswig-Holstein, age-standardized
incidence of both BCC and SCC followed an uptrend with
a peak around 2004–2005, followed by a decline until
the nation-wide skin cancer screening began in 2008.
Re-introduction of screening in Schleswig-Holstein in 2008
resulted in an increased incidence although not as sharp as
in the period when the pilot project of skin cancer screening
was first introduced in 2003. In Saarland, the time trend
suggests a moderate incidence increase until 2008, when the
nation-wide skin cancer screening began and incidence
steeply increased.
All localizations (except lips in men with SCC) were
affected by the incidence increase from the pre-SCREEN
period in 1998–2000 to the most recent period with
screening in 2008–2010 in Schleswig-Holstein (Table 4).
Overall incidence as well as BCC and SCC incidence for
tumors of the lips, eyelid, face, and arm and shoulder
increased more substantially in women than in men, but for
the scalp the incidence increase was more pronounced in men
than in women. For external ear, trunk, and leg and hip, the
results by sex and histology were ambiguous. A much higher
incidence increase of usually covered body sites was found
compared with routinely visible body sites, for both sexes and
for BCC as well as for SCC.
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DISCUSSION
The first objective of this analysis was to provide up-to-date
NMSC incidence data from a German population-
based cancer registry (Schleswig-Holstein) in a period
surrounding intensive skin cancer screening. Amidst the
current national skin cancer screening most recent data
(July 2008–December 2010) indicates an annual European
standardized incidence rate of 119.0/100,000 for women
and 145.3/100,000 for men in Schleswig-Holstein. This is
substantially higher than 10 years earlier without skin
cancer screening (81.5/100,000 for women and 111.5/
100,000 for men).
NMSC comprises two main types with different etio-
logies, SCC and BCC. A main risk factor for SCC is chronic
exposure to UV light (Rosso et al., 1996). For BCC,
intermittent sun exposure is a more important risk factor
than total sun exposure, especially in poor tanners (Kricker
et al., 1995; Rosso et al., 1996; Samarasinghe and Madan,
2012). SCCs are most frequently diagnosed on body sites with
quite constant sun exposure (Stang et al., 2003). In our
analysis, SCC and BCC incidence are both rising, but SCC
incidence grows faster than BCC incidence, and it is also
increasing steeply in very old men, whose skin may have
accumulated the damage because of sun exposure over
many years.
Within Germany, Schleswig-Holstein had one of the
highest NMSC incidence rates of all 16 federal states (age-
standardized incidence rate (European standard population) in
2010 ranged between 36/100,000 (women) and 57/100,000
(men) in Bavaria and 130/100,000 (women) and 174/100,000
(men) in Rhineland-Palatinate; Association of Population-
based Cancer Registries in Germany (GEKID), 2013).
Table 1. Incidence of non-melanoma skin cancer before and after implementation of a skin cancer screening in
Schleswig-Holstein
Women Men
Jan 1998–Dec
2000
Jul 2008–Dec
2010
Jan 1998–Dec
2000
Jul 2008–Dec
2010
N % EASR N % EASR N % EASR N % EASR
Total 5,355 100.0 81.5 7,302 100.0 119.0 5,305 100.0 111.5 7,688 100.0 145.3
Age group
o40 165 3.1 8.2 164 2.2 11.1 109 2.1 5.1 76 1.0 5.0
40–59 1,104 20.6 99.7 1,305 17.9 121.8 1,056 19.9 93.7 1,061 13.8 97.9
60–79 2,716 50.7 305.7 4,024 55.1 491.6 3,229 60.9 453.1 5,084 66.1 685.2
80þ 1,370 25.6 565.3 1,809 24.8 732.6 911 17.2 1,008.8 1,467 19.1 1,247.9
Histology
BCC 4,501 84.1 71.1 6,017 82.4 102.5 4,281 80.7 90.0 5,933 77.2 113.8
SCC 797 14.9 9.6 1,225 16.8 15.6 967 18.2 20.3 1,675 21.8 30.0
Adenocarcinoma 17 0.3 0.2 10 0.1 0.2 16 0.3 0.3 18 0.2 0.4
Sarcoma 13 0.2 0.3 15 0.2 0.3 13 0.2 0.3 28 0.4 0.5
Merkel cell carcinoma 9 0.2 0.1 22 0.3 0.3 11 0.2 0.2 23 0.3 0.4
Other 18 0.3 0.2 13 0.2 0.2 17 0.3 0.3 11 0.1 0.2
Body site
Usually visible
Lips 119 2.2 1.8 164 2.2 2.7 114 2.1 2.4 122 1.6 2.3
Eyelid 309 5.8 5.0 411 5.6 6.8 216 4.1 4.6 254 3.3 5.1
External ear 77 1.4 1.0 115 1.6 1.5 334 6.3 7.0 563 7.3 9.9
Face 2,585 48.3 36.8 3,287 45.0 49.4 2,310 43.5 48.6 2,987 38.9 56.1
Usually covered
Scalp 392 7.3 5.7 413 5.7 6.4 418 7.9 8.8 688 8.9 12.7
Trunk 844 15.8 15.3 1,330 18.2 25.8 878 16.6 18.3 1,498 19.5 29.3
Arm and shoulder 372 6.9 5.7 645 8.8 10.9 488 9.2 10.3 767 10.0 14.5
Leg and hip 344 6.4 5.2 545 7.5 8.9 189 3.6 3.9 352 4.6 6.7
Overlapping 4 0.1 0.0 1 0.0 0.0 5 0.1 0.1 4 0.1 0.1
Not otherwise specified 309 5.8 5.0 391 5.4 6.6 353 6.7 7.4 453 5.9 8.4
Abbreviations: BCC, basal cell carcinoma; EASR, age-standardized incidence rates (n/100,000, European standard population); SCC, squamous cell cancer.
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A recent systematic review (Lomas et al., 2012) has
investigated all observational studies on NMSC incidence.
Here, the pre-SCREEN incidence rates of Schleswig-Holstein
were in the middle field of the presented data. Dutch cancer
registry data show lower BCC and SCC incidence in 2005
(approximately 25%; Holterhues et al., 2010), but a recent
Table 2. Age-standardized non-melanoma skin cancer incidence rates (n/100,000, European standard population)
and 95% confidence intervals in four time periods
Schleswig-Holstein Saarland
Women Men Women Men
Pre-SCREEN period (January 1998–December 2000)
Total 81.5 (79.1, 83.8) 111.5 (108.5, 114.5) 54.3 (51.4, 57.3) 80.9 (76.8, 85.1)
BCC 71.1 (68.8, 73.3) 90.0 (87.3, 92.7) 44.7 (41.9, 47.4) 62.1 (58.5, 65.7)
SCC 9.6 (8.8, 10.3) 20.3 (19.0, 21.6) 7.7 (6.7, 8.7) 17.2 (15.3, 19.1)
SCREEN period (July 2003–June 2004)
Total 119.6 (114.7, 124.5) 149.3 (143.6, 155.1) 58.2 (52.9, 63.6) 81.9 (75.0, 88.8)
BCC 105.0 (100.4, 109.6) 119.8 (114.6, 124.9) 49.1 (44.0, 54.1) 63.8 (57.7, 69.8)
SCC 13.0 (11.6, 14.4) 27.9 (25.4, 30.4) 7.0 (5.5, 8.6) 17.2 (14.0, 20.4)
Between period (July 2004–June 2008)
Total 113.1 (110.8, 115.4) 144.1 (141.4, 146.9) 65.6 (62.8, 68.5) 93.9 (90.3, 97.6)
BCC 96.4 (94.2, 98.6) 114.1 (111.6, 116.5) 55.4 (52.7, 58.1) 72.5 (69.3, 75.7)
SCC 15.4 (14.6, 16.1) 28.6 (27.4, 29.8) 8.6 (7.6, 9.5) 19.9 (18.2, 21.6)
Nation-wide skin cancer screening period (July 2008–December 2010)
Total 119.0 (116.1, 122.0) 145.3 (141.9, 148.6) 96.5 (92.0, 100.9) 131.1 (125.8, 136.3)
BCC 102.5 (99.7, 105.3) 113.8 (110.8, 116.8) 83.4 (79.1, 87.6) 103.2 (98.5, 107.9)
SCC 15.6 (14.7, 16.6) 30.0 (28.5, 31.4) 12.2 (10.9, 13.6) 25.7 (23.5, 28.0)
Abbreviations: BCC, basal cell carcinoma; SCC, squamous cell cancer; SCREEN, Skin Cancer Research to Provide Evidence for Effectiveness of Screening in
Northern Germany.
Table 3. Absolute differences in age-standardized non-melanoma skin cancer incidence rates (n/100,000, European
standard population) and 95% confidence intervals
Schleswig-Holstein Saarland P-value1
Women Men Women Men Women Men
Pre-SCREEN period (January 1998–December 2000) to SCREEN period (July 2003–June 2004)
Total 38.1 (32.7, 43.5) 37.9 (31.4, 44.3) 3.9 ( 2.2, 10.0) 1.0 ( 7.1, 9.0) o0.001 o0.001
BCC 34.0 (28.8, 39.1) 29.8 (23.9, 35.6) 4.4 ( 1.3, 10.1) 1.7 ( 5.4, 8.8) o0.001 o0.001
SCC 3.5 (1.8, 5.1) 7.6 (4.9, 10.4) 0.7 ( 2.5, 1.1) 0.0 ( 3.8, 3.7) 0.001 0.001
SCREEN period (July 2003–June 2004) to between period (July 2004 –June 2008)
Total  6.5 ( 11.9, 1.1) 5.2 (11.6, 1.1) 7.4 (1.3, 13.4) 12.1 (4.3, 19.9) 0.001 0.001
BCC  8.6 ( 13.7, 3.5) 5.7 (11.4, 0.0) 6.4 (0.7, 12.1) 8.7 (1.9, 15.6) o0.001 0.001
SCC 2.4 (0.7, 4.0) 0.7 (2.0, 3.5) 1.5 ( 0.3, 3.3) 2.7 ( 0.9, 6.3) 0.509 0.397
Between period (July 2004–June 2008) to nation-wide screening period (July 2008–December 2010)
Total 6.0 (2.2, 9.7) 1.1 (3.2, 5.5) 30.9 (25.6, 36.2) 37.1 (30.8, 43.5) o0.001 o0.001
BCC 6.1 (2.5, 9.6) 0.2 (4.1, 3.6) 27.9 (22.9, 32.9) 30.7 (25.1, 36.4) o0.001 o0.001
SCC 0.2 ( 1.0, 1.5) 1.3 (0.6, 3.2) 3.7 (2.0, 5.3) 5.8 (3.0, 8.6) 0.001 0.009
Abbreviations: BCC, basal cell carcinoma; SCC, squamous cell cancer; SCREEN, Skin Cancer Research to Provide Evidence for Effectiveness of Screening in
Northern Germany.
Bold numbers indicate statistical significance (Pp0.05).
1Comparison between Schleswig-Holstein and Saarland.
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observational study (2009) from the Netherland higher BCC
incidence (54% women and 31% men; Flohil et al., 2013).
Rates for BCC in Denmark were about 25% higher in 2007
(Birch-Johansen et al., 2010). In England, incidence rates for
BCC from population-based cancer registries in 2000–2006
were close to those of Schleswig-Holstein, while Scotland and
Northern Ireland had lower rates (approximately 10%). Inci-
dence rates for SCC for England, Scotland, and Northern
Ireland showed no relevant differences to Schleswig-Holstein
(Lomas et al., 2012). So all in all, our data fit quite well in
the pattern of NMSC incidence in Europe. But it has to be
added that the closer look on NMSC incidence in the
presented literature revealed extreme heterogeneity, which is
very likely caused by different registration methods, coding
and analysis of NMSC. This heterogeneity is even more
obvious when using official cancer registry data, provided
by the International Association for Research on Cancer in
Cancer Incidence in Five Continents (International Association
for Research on Cancer, 2010). But even when regional
comparisons of NMSC are hampered, temporal analyses
within one region seem to be reliable when the registration
method was stable over time. This applies at least to our
study region.
The second objective of this analysis was to study the
impact of skin cancer screening on NMSC incidence in
Schleswig-Holstein and Saarland. The age-standardized
NMSC incidence rate in Schleswig-Holstein increased from
81.5 to 119.6/100,000 for women and from 111.5 to 149.3/
100,000 for men in the pre-SCREEN period to the SCREEN
period. Such incidence peaks are commonly observed during
the introduction of screening programs (Esserman et al., 2009).
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Figure 1. Trends in age-standardized incidence rates (per 100,000,
European standard population) of BCC and SCC by sex. (a) Schleswig-
Holstein: during the field trial in 2001, about 200 physicians were trained
in an 8-hour training course and 5,425 screening examinations were
conducted, leading to an increased awareness among physicians and the
population. During SCREEN (2003/2004), a population-based screening
with 360,288 participants was conducted (Breitbart et al., 2012). In 2008,
a nation-wide biennial skin cancer screening was introduced for persons
aged 35 years or older with statutory health insurance. (b) Saarland: in 2008,
a nation-wide biennial skin cancer screening was introduced for persons aged
35 years or older with statutory health insurance. BCC, basal cell carcinoma;
EASR, age-standardized incidence rates; SCC, squamous cell cancer.
Table 4. Percentage change of EASR of BCC and
SCC tumors from pre-screening (January
1998–December 2000) to screening period by body
site (July 2008–December 2010) in Schleswig-Holstein
Total BCC SCC
Women Men Women Men Women Men
Usually visible 35.6* 17.2* 32.8* 12.5* 54.3* 36.4*
Lips 50.5*  5.4 45.1* 27.6 67.6*  20.8
Eyelid 37.6* 11.2 34.8* 8.2 88.7* 37.0
External ear 50.1* 41.1* 36.1 42.4* 117.2* 42.2*
Face 34.2* 15.4* 31.9* 10.1* 49.2* 45.4*
Usually covered 63.0* 53.3* 61.3* 49.2* 82.6* 73.0*
Scalp 11.9 44.5* 8.5 31.1* 60.5 79.8*
Trunk 68.8* 60.1* 68.0* 58.0* 88.8* 105.3*
Arm and
shoulder
92.3* 41.5* 88.7* 34.0* 108.9 52.2*
Leg and hip 70.5* 71.9* 76.4* 72.8* 42.6 86.2*
Not otherwise
specified
32.9* 14.0 35.0* 13.7 49.6 21.4
Abbreviations: ASR, age-standardized rate; BCC, basal cell carcinoma;
EASR, age-standardized incidence rates (n/100,000, European standard
population); SCC, squamous cell carcinoma.
*Po0.05.
Bold numbers indicate statistical significance (p0.05). Percentage change
is calculated as (ASR_2–ASR_1)/ASR_1.
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During the same time period in absence of skin cancer
screening, no incidence peak was observed in the reference
region (Saarland). SCREEN participation was higher among
women than men (Waldmann et al., 2012), which was
associated with larger NMSC incidence increases (47%
vs 34%).
The impact of SCREEN was similar for NMSC compared
with melanoma, where incidence increases of 53% for
women and 26% for men were observed (Waldmann et al.,
2012), although the proportion of cases diagnosed via
SCREEN was a little lower than for melanoma (approxi-
mately 38% instead of 50%). Although it is intriguing that
the development of NMSC as well as of melanoma incidence
matches the course expected of an effective screening, it is still
entirely possible that a small part of the incidence increase
was artificial and caused by a heightened notification effort.
Again, as expected after the end of a screening project (and as
observed for melanoma; Waldmann et al., 2012), incidence
dropped in the period between SCREEN and nation-wide skin
cancer screening, when reimbursement for conducting a
preventive whole-body skin examination was not universal.
The incidence of NMSC did not return to the pre-SCREEN
level because of two possible reasons: first, some health
insurances continued to offer skin cancer screening to their
insurancees (estimated o10% of population). Second,
the training of the physicians may have had a lasting effect
and influenced their diagnostic behavior even without
a reimbursement for screening. During the time period of
SCREEN and before the implementation of the nation-wide
skin cancer screening in 2008, only a moderate incidence
increase was observed for the reference region (Saarland). A
certain amount of additionally detected cases may therefore
be due to a time trend unrelated to screening activities, as it
has been observed in other countries like Finland, Scotland,
and the Netherlands (Flohil et al., 2013). With the uptake
of nation-wide screening, incidence significantly rose again
in Schleswig-Holstein, but only slightly because the rates
had not decreased that much after SCREEN. For Saarland,
on the contrary, a large incidence increase was observed, well
beyond the previous annual increases (þ 47% for women and
þ 40% for men). Interestingly, this increase in Saarland
was almost similar compared with the increase following
the first introduction of skin cancer screening in Schleswig-
Holstein several years before. The observed incidence
increases after the beginning of the skin cancer screening
in Schleswig-Holstein in 2003 and in Saarland in 2008 are in
accordance with observations of other screening programs.
For example, for mammography screening, breast cancer
incidence increases of 20–30% were observed in Spain
(Pollan et al., 2010) during screening implementation,
in Norway incidence doubled (Hofvind et al., 2008). After
colonoscopy screening, the incidence of invasive colorectal
cancer in Germany increased by 13% and the incidence of
in situ cancers by 52% (Schnoor et al., 2012). Prostate-specific
antigen screening was followed by an increase in prostate
cancer of 134% in the Slovak Republic and 196% in
the Czech Republic (Langagergaard et al., 2013). The
extreme incidence peaks observed directly after screening
implementation (Schleswig-Holstein in 2003 and Saarland in
2008) are strong arguments for an impact of the skin cancer
screening.
In agreement with many other studies, we found that the
body site distribution of NMSC differs between women and
men. Moreover, the increase of NMSC incidence differs by sex
and body site. Women were nearly three times more likely to
participate in screening than men. As a result, the body site–
specific increase was generally higher in women than in men,
except for tumors of the scalp where the incidence rate
increase in men was four times as high as in women. Although
the face remained the far most frequent localization for
NMSC, the increase in incidence rates was even greater in
most other body sites, especially arm and shoulder, leg and
hip, and trunk. The trunk was also found to be one of the body
sites with the largest incidence increases in a Dutch analysis
(de Vries et al., 2004) as well as in several studies on
melanoma (Downing et al., 2006; Bradford et al., 2010),
which may be related to a more sun-seeking behavior and sun
bed use. Arm and shoulder, leg and hip, and trunk are often
exposed to UV radiation during summer or when using sun
beds, but they are not easily accessible to visual examination
for untrained physicians. Previous to the SCREEN training
program, physicians were looking for skin cancers very likely
only on sun-exposed body parts, mainly on the face and
hands. Owing to the improved education to perform a whole-
body skin examination from scalp to toe, they can now detect
a high number of otherwise unnoticed lesions on usually
covered body sites.
Regarding strength and limitations of this analysis, data
quality is the most important issue. Completeness of registra-
tion of the population-based Schleswig-Holstein Cancer Reg-
istry was shown by the external review of the German Centre
for Cancer Registry Data, which was done for all cancer sites
(excluding NMSC) and particularly for melanoma of the skin
(Robert Koch Institute and the Association of Population-based
Cancer Registries in Germany, 2012). Even if this assessment
did not include NMSC, an incomplete registration is unlikely
because of the overall good performance of the cancer
registry. We are confident that temporal changes in NMSC
incidence are most dominantly caused by external factors
such as skin cancer screening or real increases in incidence.
As melanoma and NMSC are reported to registries by the same
physicians (dermatologists and pathologists), changes in
notification behavior are limited. However, even when
unlikely, it cannot be ruled out that the increased number of
cases was due in part to increased notification related to the
screening rather than real incidence increases. NMSC
incidence is reported to be rising in Western countries. In
order to distinguish between a time trend unrelated to
screening activities and an increase because of skin cancer
screening, a comparison with another German federal state
with a long history of population-based cancer registration and
without skin cancer screening until July 2008 was conducted
(Federal State of Saarland).
A previous publication (Katalinic et al., 2003) based on data
from the Cancer Registry Schleswig-Holstein reported slightly
lower incidence rates for the early time period: because of late
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notifications, the number of cases for the period 1998–2001 is
now 13.5% higher. As a result of improved cancer registration,
under-ascertainment for the recent data is unlikely. Even with
a small under-registration for the most recent 1 or 2 years, our
analysis would give a more conservative effect of skin cancer
screening.
Finally, it has to be mentioned that the evidence given by
our results is restricted to the feasibility and the general
effectiveness (in terms of detecting skin cancer) of a popula-
tion-based skin cancer screening. Many questions are still
open. The benefits and harms of a skin cancer screening,
especially when targeting NMSC, have to be assessed. If the
benefits outweigh the harms, economic questions in terms of
cost-effectiveness have to be answered.
Despite these open questions, we recommend, based on the
experiences of the SCREEN project, that the skin cancer
screening should be population based, ideally including an
invitation system. The screening test, i.e., the whole-body
examination, should be performed with highest possible
quality and standardization. Training programs for general
practitioners as well as for dermatologist should be mandatory.
Conclusion
We provide up-to-date NMSC incidence amidst nation-wide
skin cancer screening for the Federal State of Schleswig-
Holstein, Germany. The observed incidence for the pre-
screening period conforms to the pattern of NMSC incidence
in Europe. Further, with the introduction of a pilot skin cancer
screening (SCREEN) a pronounced incidence increase was
observed, very consistent in different subgroups (sex, age,
histology, and body site). No such increase occurred in a
reference region without skin cancer screening (Federal State
of Saarland, Germany) until the implementation of a nation-
wide skin cancer screening in 2008. Then the incidence
increase was similar to that observed in Schleswig-Holstein
for SCREEN.
Despite the inherent methodological limitations of an
ecological study for establishing causal inferences, the inci-
dence increases can most likely be attributed to the skin
cancer screening. Such screening may improve NMSC treat-
ment by earlier diagnosis and hopefully reduce recurrences
and overall costs of NMSC. However, it cannot be ruled
out that screening might increase morbidity and costs if a
substantial proportion of the additionally detected lesions
would otherwise not have been noticed during the patient’s
lifetime.
MATERIALS AND METHODS
The Cancer Registry in Schleswig-Holstein covers the northernmost
federal state of Germany with a population of 2.8 million inhabitants.
Since 1998, all residents with a diagnosis of cancer are registered via
a mandatory notification system. The Saarland Cancer Registry covers
a population of 1.2 million and has the longest uninterrupted
history of population-based cancer registration in Germany. Both
registries are full voting members of the International Association
of Cancer Registries, indicating high quality and completeness
of cancer registration. For both registries, data are available up to
2010.
The tumor diagnoses are encoded by the 10th revision of the
International Statistical Classification of Diseases and Related Health
Problems (ICD-10 classification; World Health Organization, 2009),
and histology and tumor localization by the International
Classification of Diseases for Oncology (3rd edn; Fritz et al., 2000).
NMSC is defined as ICD-10 diagnosis C44. The definition of the
histological subgroups is based on the ICD-O-3 codes provided by
the Technical Report No. 40 of the International Agency for Research
on Cancer (Tyczynski et al., 2003). Tumor localization was defined
by the fourth digit of the ICD-10 code.
For multiple primaries, rules of the International Association of
Cancer Registries are used (IARC, 2004), meaning that for skin cancer
at most one melanoma, one BCC, and one SCC per person are
considered for incidence calculations. In Schleswig-Holstein, the
exact date of diagnosis or the histological type of the recorded
primary NMSC was unknown in a few cases (5.6%). These cases were
excluded, leading to slight underestimation of incidence. Death
certificate-only cases were excluded because of missing information
on date of incidence, histology, and localization, (Schleswig-
Holstein: 316 cases, 0.4% and Saarland: 9 cases, o0.1%).
Depending on the research question, different subperiods were
chosen. Up-to-date NMSC incidence numbers were derived from
July 2008 to December 2010 (national skin cancer screening)
data and presented together with data from 10 years earlier (January
1998–December 2000, no screening). The analysis of the impact of
skin cancer screening on NMSC incidence is based on four periods:
the pre-SCREEN period (January 1998–December 2000), the SCREEN
period (July 2003–June 2004), the period between SCREEN and
nation-wide skin cancer screening (July 2004–June 2008), and the
skin cancer screening period (July 2008–December 2010). The period
immediately before the SCREEN period (January 2001–June 2003)
was excluded in order to minimize carry-over effects.
Incidence rates were calculated as crude and age-standardized
rates in 100,000 person years using European and world standard
populations. For results of crude world standardized incidence rates
see Supplementary Information online.
Incidence numbers are reported as absolute numbers and as
relative frequencies by subgroup. Absolute changes in age-standar-
dized rates from one period to the next or between the two regions
were tested by using the normal approximation for the Poisson
distributed number of cases within 5-year age groups.
Statistical significance was defined as P-valueo0.05. Statistical
computation was conducted with R 15.3. (R Development Core
Team, 2013)
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